WLLW vs. CTX, VPH, DN, LABS, MDP, AEZS, TMD, RVX, and ATE
Should you be buying Willow Biosciences stock or one of its competitors? The main competitors of Willow Biosciences include Crescita Therapeutics (CTX), Valeo Pharma (VPH), Delta 9 Cannabis (DN), MediPharm Labs (LABS), Medexus Pharmaceuticals (MDP), Aeterna Zentaris (AEZS), Titan Medical (TMD), Resverlogix (RVX), and Antibe Therapeutics (ATE). These companies are all part of the "medical" sector.
Willow Biosciences (TSE:WLLW) and Crescita Therapeutics (TSE:CTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, community ranking, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.
Willow Biosciences has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, Crescita Therapeutics has a beta of 1.66, indicating that its stock price is 66% more volatile than the S&P 500.
Crescita Therapeutics received 46 more outperform votes than Willow Biosciences when rated by MarketBeat users. However, 82.35% of users gave Willow Biosciences an outperform vote while only 67.42% of users gave Crescita Therapeutics an outperform vote.
Willow Biosciences has a net margin of 0.00% compared to Crescita Therapeutics' net margin of -11.33%. Crescita Therapeutics' return on equity of -9.95% beat Willow Biosciences' return on equity.
In the previous week, Willow Biosciences and Willow Biosciences both had 1 articles in the media. Willow Biosciences' average media sentiment score of 0.00 equaled Crescita Therapeutics'average media sentiment score.
0.1% of Willow Biosciences shares are held by institutional investors. 27.3% of Willow Biosciences shares are held by insiders. Comparatively, 10.3% of Crescita Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Crescita Therapeutics has higher revenue and earnings than Willow Biosciences. Crescita Therapeutics is trading at a lower price-to-earnings ratio than Willow Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Crescita Therapeutics beats Willow Biosciences on 7 of the 13 factors compared between the two stocks.
Get Willow Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for WLLW and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding WLLW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Willow Biosciences Competitors List
Related Companies and Tools
